Literature DB >> 19590003

Induction of synaptic long-term potentiation after opioid withdrawal.

Ruth Drdla1, Matthias Gassner, Ewald Gingl, Jürgen Sandkühler.   

Abstract

mu-Opioid receptor (MOR) agonists represent the gold standard for the treatment of severe pain but may paradoxically also enhance pain sensitivity, that is, lead to opioid-induced hyperalgesia (OIH). We show that abrupt withdrawal from MOR agonists induces long-term potentiation (LTP) at the first synapse in pain pathways. Induction of opioid withdrawal LTP requires postsynaptic activation of heterotrimeric guanine nucleotide-binding proteins and N-methyl-d-aspartate receptors and a rise of postsynaptic calcium concentrations. In contrast, the acute depression by opioids is induced presynaptically at these synapses. Withdrawal LTP can be prevented by tapered withdrawal and shares pharmacology and signal transduction pathways with OIH. These findings provide a previously unrecognized target to selectively combat pro-nociceptive effects of opioids without compromising opioid analgesia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590003     DOI: 10.1126/science.1171759

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  88 in total

1.  Heterosynaptic long-term potentiation at GABAergic synapses of spinal lamina I neurons.

Authors:  Henning Fenselau; Bernhard Heinke; Jürgen Sandkühler
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

2.  Episodic withdrawal promotes psychomotor sensitization to morphine.

Authors:  Patrick E Rothwell; Jonathan C Gewirtz; Mark J Thomas
Journal:  Neuropsychopharmacology       Date:  2010-09-01       Impact factor: 7.853

3.  Opioid-induced long-term potentiation in the spinal cord is a presynaptic event.

Authors:  Hong-Yi Zhou; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

4.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Authors:  T M Largent-Milnes; T Yamamoto; P Nair; J W Moulton; V J Hruby; J Lai; F Porreca; T W Vanderah
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Withdrawal from spinal application of remifentanil induces long-term potentiation of c-fiber-evoked field potentials by activation of Src family kinases in spinal microglia.

Authors:  Tao Yang; Sujuan Du; Xianguo Liu; Xijiu Ye; Xuhong Wei
Journal:  Neurochem Res       Date:  2018-06-29       Impact factor: 3.996

6.  [To give or not to give, that is not the question here! Longterm administration of opioids for non-tumor pain (LONTS)].

Authors:  T R Tölle; R-D Treede; M Zenz
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

Review 7.  Imaging spinal cord activity in behaving animals.

Authors:  Nicholas A Nelson; Xiang Wang; Daniela Cook; Erin M Carey; Axel Nimmerjahn
Journal:  Exp Neurol       Date:  2019-06-06       Impact factor: 5.330

Review 8.  The pharmacology of nociceptor priming.

Authors:  Ram Kandasamy; Theodore J Price
Journal:  Handb Exp Pharmacol       Date:  2015

9.  Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates.

Authors:  Zilong Wang; Changyu Jiang; Qianru He; Megumi Matsuda; Qingjian Han; Kaiyuan Wang; Sangsu Bang; Huiping Ding; Mei-Chuan Ko; Ru-Rong Ji
Journal:  Sci Transl Med       Date:  2020-02-19       Impact factor: 17.956

Review 10.  Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity.

Authors:  Dimitris N Xanthos; Jürgen Sandkühler
Journal:  Nat Rev Neurosci       Date:  2013-11-27       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.